Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KIN - Kindred Biosciences Inc


Previous close
9.25
0   0%

Share volume: 178,496
Last Updated: Fri 27 Aug 2021 06:00:00 AM CEST
Pharmaceutical Preparation Manufacturing : -2.88%

PREVIOUS CLOSE
CHG
CHG%

$9.25
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
31%
Profitability 0%
Dept financing 7%
Liquidity 66%
Performance 60%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$9.25
P/E Ratio 
0.00
DAY RANGE
$9.25 - $9.25
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
45.462 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: Richard Chin
Region: US
Website: www.kindredbio.com
Employees: 63
IPO year: -
Issue type: Common Stock
Market: NASDAQ
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.

Recent news